JUNS MDXXF Pharmala Biotech executes definitive license agreement granting Jupiter Neurosciences exclusive U.S. rights to ala-002 Pharmala B

JUNS MDXXF Pharmala Biotech executes definitive license agreement granting Jupiter Neurosciences exclusive U.S. rights to ala-002 Pharmala Biotech - deal valued up to $100M including $3.33M upfront and milestones plus royalties - Upfront payment of $3.33M: $1.50M cash, $1.83M in Jupiter stock - Development and regulatory milestones up to $23.33M including $20M for FDA approval - Commercialization milestones up to $73.33M based on U.S. net sales targets - To receive 3% Royalty on U.S. net sales after third milestone - To manufacture gmp-grade ala-002 for Jupiter under separate supply agreement